Proactive Investors - Run By Investors For Investors

Admedus delivers $25.6 million in total group revenue for the 2018 financial year

New sales teams and product expansion led the continued growth in ADAPT sales in all regions for the period ending December 31, 2018.
Medical solutions image
Admedus delivers life-changing solutions to help healthcare professionals

Admedus Ltd (ASX:AHZ) has delivered revenue of $25.6 million for the financial year ending December 31, 2018, up 20% year-on-year versus the total group revenue of $21.4 million in 2017.

In December 2017 Admedus changed its financial year-end from June 30 to December 31 to align the company’s financial reporting with its global business sales cycle.

Most of the revenue growth was driven by ADAPT technology sales, which is used to repair congenital heart deformities and more complex heart defects.

ADAPT sales grew 55% year-on-year to $11.1 million compared to $7.2 million in 2017.

The increase was driven by sales in North America, which is the first market where the expanded 3D product range including CardioCel, CardioCel Neo and VascuCel launched last year.

READ: Admedus reports $6.3 million revenues amid $12.7 million Star Bright backing

Admedus managing director and chief executive officer Wayne Paterson said: “The developments over the past year form a solid basis for a sustainable global business.

“ADAPT revenue growth was 55% over the previous year which is significantly higher than cost growth.

“Uptake throughout 2018 continued to increase, as more key opinion leaders and surgeons have started to use or increased their utilisation of ADAPT treated products.

“The company continues to take market share away from large and more established competitors via superior clinical data, increasing KOL advocacy and an expanding portfolio of unique products.”

READ: Admedus receives first data from animal study on heart valve device

Selling, general and administration expenses (SG&A), including research and development spend, was $34.3 million for 2018.

In 2018 SG&A costs for ADAPT declined as a percentage of revenue from 142% to 122%, with gross profit for the group for the year being $12.4 million, representing a gross profit margin of 49%.

Net loss after tax was marked at $24.7 million and the closing cash balance on December 31, 2018, was $12 million, up from $8.3 million on December 31, 2017.

READ: Admedus secures $8.6 million as Sio Partners becomes substantial holder

Paterson added: “Our 3D aortic valve, the central component of our TAVR device is also progressing and we’re working closely with our TAVR medical advisory board who are helping direct our engineers to develop a unique and competitive TAVR device.

“The current market worth is estimated to be upwards of US$12 billion by 2025 and these new products will help the company continue to expand into the larger adult market while maintaining high levels of adoptions in the niche paediatric segments.” 

View full AHZ profile View Profile

Admedus Ltd Timeline

Related Articles

A man's knee pain is highlighted with a red area that points to inflammation
January 22 2019
The injectable PPS trial has had a clinically meaningful and statistically significant result in patients with arthritic knee pain.
Scientists in a lab
January 30 2019
CEO Gary Phillips says Pharmaxis’ healthy cash balance gives it time to choose between in-house and partnering options.
human kidneys
May 06 2019
The Danish company is seeking FDA approval of the test for use in both adults and children
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use